MOREPENLAB share price, P/E, ROE & financials

As of 6 Nov 2026, Morepen Laboratories trades at 26.9× trailing earnings, below the industry P/E of 28.7×, and the shares are 39% below their 52-week high. Sales and net profit grew 8.4% and 35% a year over 3 years; its ROCE of 9.4% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.23× equity, and its dividend yield is 0.2%. It is a small-cap company with a market cap of ₹5,055 Cr, ranked 43rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 101% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹94.10
Day high: ₹95.40
Day low: ₹92.25
Prev. close: ₹97.10
Volume: 61.8 L

Health check

1 good · 3 fair · 2 to check

ReturnsAhead
+101.5% over a year, better than 6 of 7 peers.
Price tagIn line
P/E 26.9 vs industry 28.7.
GrowthSteady
Sales +8.4%, profit +34.9% a year over 3 years.
ProfitabilityWeak
ROCE 9.4% vs peer median 17.9%.
Balance sheetFair
Debt 0.23× equity, interest covered 8.5×, Piotroski 4 of 9.
Red flags1 to check
39% below its 52-week high.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹5,055 Cr, #43 of 154 in its industry by size.

Moves with the market

Beta 0.95 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Sep 2026: sales ₹2,286 Cr · profit ₹187 Cr

Market cap: ₹5,055 Cr; Small cap
P/E: 26.9; Industry 28.7
Price to book: 3.66; Peers 4.99
Dividend yield: 0.22%
ROE: 14.6%; Peers 14.7%
ROCE: 9.4%; Peers 17.9%
Debt to equity: 0.23; Debt ₹323 Cr
EPS (TTM): ₹3.43; Face value ₹2
OPM (TTM): 12.1%; Net margin 8.2%
Sales growth: +81.4%; Latest quarter vs a year ago
Profit growth: +117.5%; Latest quarter vs a year ago
Price to sales: 2.21; EV/EBITDA 19.6

Strengths

Quarterly profit up 117.5% on a year ago.
Quarterly sales up 81.4% on a year ago.

Risks to check

39% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Morepen Laboratories

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, NASH/ MASH treatment products, CKD treatment, and anti-depressant drugs; and home diagnostic…

Headquarters: Gurugram
Employees: 1,919
Sector: Healthcare
ISIN: INE083A01026
Website: morepen.com

Price range

52 weeks

₹33.05₹150.70

Today

₹92.25₹95.40

Avg volume (3M): 1.7 Cr
1-year return: plus 101.5%
From 52-week high: minus 38.8%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
MOREPENLABMorepen Laboratories	92.25	minus 4.99%	5,055	26.9	3.66	9.4%	14.6%	15.1%	8.4%	34.9%	0.22%	plus 101.5%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
412	484	485	570	747
381	438	460	488	623
30.7	46.3	24.4	82.5	123
7.5%	9.6%	5.0%	14.5%	16.5%
4.6	3.8	8.5	5.2	8.7
4.2	4.3	3.9	4.8	5.2
11.3	10.4	5.7	8.3	10.1
25.8	–	–	–	–
45.7	35.4	23.3	74.5	117
10.2%	22.4%	32.6%	24.4%	23.7%
40.9	27.5	15.7	56.4	88.9
0.75	0.50	0.28	1.03	1.62

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +8.4%
Profit CAGR 3Y: +34.9%
EPS CAGR 3Y: +31.0%
ROE: 14.6%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1,414	1,682	1,804	1,801
–	+19.0%	+7.2%	minus 0.1%
1,334	1,524	1,630	1,676
79.5	159	174	126
5.6%	9.4%	9.7%	7.0%
6.1	14	17.8	21
2	3.7	7.8	16.1
27.9	33.5	29	36.4
–	–	–	25.8
55.8	135	155	120
30.6%	28.6%	23.9%	20.2%
38.7	96.2	118	94.9
–	+148.6%	+22.7%	minus 19.6%
0.77	1.88	2.20	1.73

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
102	102	110	110
651	745	1,047	1,137
25.2	29	105	208
332	417	517	482
1,110	1,293	1,778	1,936
248	301	457	544
80.7	88.1	115	150
–	1.3	7.2	101
21.7	16.9	138	54.1
761	886	1,061	1,086
1,110	1,293	1,778	1,936

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−91.2	73.4	32.1	32.6
−46.5	−83.3	−322	−123
144	5.2	300	97.4
5.9	−4.7	10.4	6.6
−46	−81.3	−214	−161
−137	−8	−182	−128
–	–	–	−10.9

Shareholding pattern

Source: NSE filings

35.6%

promoters

Promoters35.65%
Public64.35%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	35.65%	64.35%	0.00
30 Jun 2026	35.65%	64.35%	0.00
31 Mar 2026	35.65%	64.35%	0.00
31 Dec 2025	35.65%	64.35%	0.00
30 Sep 2025	35.65%	64.35%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you